These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30026343)

  • 1. Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in
    Borsi E; Martello M; Santacroce B; Zamagni E; Tacchetti P; Pantani L; Mancuso K; Rocchi S; Cavo M; Terragna C
    Haematologica; 2018 Dec; 103(12):e602-e606. PubMed ID: 30026343
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pomalidomide for multiple myeloma.
    Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
    Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.
    Bringhen S; Mina R; Cafro AM; Liberati AM; Spada S; Belotti A; Gaidano G; Patriarca F; Troia R; Fanin R; De Paoli L; Rossi G; Lombardo A; Bertazzoni P; Palumbo A; Sonneveld P; Boccadoro M
    Leukemia; 2018 Aug; 32(8):1803-1807. PubMed ID: 29479061
    [No Abstract]   [Full Text] [Related]  

  • 5. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
    Das DS; Ray A; Song Y; Richardson P; Trikha M; Chauhan D; Anderson KC
    Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo.
    Jarauta V; Jaime P; Gonzalo O; de Miguel D; Ramírez-Labrada A; Martínez-Lostao L; Anel A; Pardo J; Marzo I; Naval J
    Cancer Lett; 2016 Nov; 382(1):1-10. PubMed ID: 27565383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
    Salvini M; Bonello F; Boccadoro M; Larocca A
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):75-87. PubMed ID: 27894203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel drug combinations for the management of relapsed/refractory multiple myeloma.
    Usmani SZ; Lonial S
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S71-7. PubMed ID: 25486960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.
    Scott A; Weber N; Tiley C; Taylor K; Taper J; Harrison S; Chan KL; Stark R; Lee C; Morris K; Ho PJ; Dodds A; Ramanathan S; Ramakrishna R; Watson AM; Auguston B; Kwok F; Quach H; Warburton P; Rowlings P; Mollee P
    Leuk Lymphoma; 2018 Jun; 59(6):1514-1516. PubMed ID: 29022836
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient.
    Schäfer J; Welti L; Seckinger A; Burhenne J; Theile D; Weiss J
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):71-79. PubMed ID: 28500557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple Myeloma--Better Drugs Ask for More Stringent Evaluations.
    Sonneveld P
    JAMA Oncol; 2015 Sep; 1(6):754-5. PubMed ID: 26181637
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone].
    Rasche L; Einsele H; Nitschmann S
    Internist (Berl); 2019 Jun; 60(6):658-660. PubMed ID: 30941437
    [No Abstract]   [Full Text] [Related]  

  • 14. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.
    Thompson RM; Dytfeld D; Reyes L; Robinson RM; Smith B; Manevich Y; Jakubowiak A; Komarnicki M; Przybylowicz-Chalecka A; Szczepaniak T; Mitra AK; Van Ness BG; Luczak M; Dolloff NG
    Oncotarget; 2017 May; 8(22):35863-35876. PubMed ID: 28415782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
    Palmas A; Piras G; Uras A; Asproni R; Murineddu M; Monne M; Stradoni R; Latte G
    Future Oncol; 2017 Feb; 13(5s):7-9. PubMed ID: 28116939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
    Okabe S; Tanaka Y; Tauchi T; Ohyashiki K
    Ann Hematol; 2019 Mar; 98(3):723-733. PubMed ID: 30430191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.
    Chauhan D; Singh AV; Ciccarelli B; Richardson PG; Palladino MA; Anderson KC
    Blood; 2010 Jan; 115(4):834-45. PubMed ID: 19965674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.
    Conticello C; Parisi M; Romano A; Calafiore V; Ancora F; La Fauci A; Consoli ML; Di Raimondo F
    Future Oncol; 2017 Feb; 13(5s):3-6. PubMed ID: 28116941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
    Boudreault JS; Touzeau C; Moreau P
    Expert Rev Hematol; 2017 Mar; 10(3):207-215. PubMed ID: 28110581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.